Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade

Seoul National University Hospital462 enrolled

Overview

1. Neoadjuvant treatment (NAT) is increasingly used in managing pancreatic ductal adenocarcinoma (PDAC), necessitating dependable methods to evaluate tumor response. 2. Among various pathological tumor regression grading systems, the College of American Pathologists (CAP) system is commonly used to predict chemo-responsiveness and survival. 3. This study aimed to analyze long-term survival outcomes based on pathologic response using the CAP grade after NAT in PDAC and to identify clinicopathologic factors that influence a favorable pathologic response.

Study Type

OBSERVATIONAL

Enrollment

462

Conditions

Pancreatic Cancer Neoadjuvant Therapy Pathological Complete Response

Interventions

neoadjuvant therapyDRUG

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (aged \>18 years) who underwent pancreatic resection after NAT at a single center between January 2009 and December 2023. * Patients were initiated on NAT after confirming PDAC diagnosis based on pathological examination. Exclusion Criteria: * Patients without a reported CAP grade * Patients who underwent palliative surgery * Patients who received NAT outside the specified protocol due to incomplete information.

Outcomes

Primary Outcomes

5-year overall survival

from diagnosis to any cause of death

Time frame: assessed up to 60months

5-year disease-free survival

defined as the duration between the date of surgery and the occurrence of the first instance of recurrence, death, or the last follow-up date.

Time frame: assessed up to 60months